| Lisa R Rogers, DO | |
|
2333 Biddle Ave, Wyandotte, MI 48192-4668 | |
| (313) 916-2723 | |
| Not Available |
| Full Name | Lisa R Rogers |
|---|---|
| Gender | Female |
| Speciality | Neurology |
| Experience | 48 Years |
| Location | 2333 Biddle Ave, Wyandotte, Michigan |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1124109251 | NPI | - | NPPES |
| 4850149 | Medicaid | MI | |
| P00880297 | Other | OH | RR MEDICARE |
| 0569157 | Medicaid | OH |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2084N0400X | Psychiatry & Neurology - Neurology | 34.003427 (Ohio) | Secondary |
| 2084N0400X | Psychiatry & Neurology - Neurology | 5101011925 (Michigan) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Henry Ford Hospital | Detroit, MI | Hospital |
| Henry Ford Wyandotte Hospital | Wyandotte, MI | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Henry Ford Medical Group | 0547178311 | 2095 |
| Henry Ford Wyandotte Hospital | 2264334499 | 146 |
News Archive
Research conducted at Leiden has established that guts-on-chips respond in the same way to aspirin as real human organs do. This is a sign that these model organs are good predictors of the effect of medical drugs on the human body. Publication in Nature Communications on 15 August.
Johns Hopkins scientists have launched a pioneering research program to create, for the first time, human platelet cells from stem cells in order to study inherited blood clotting abnormalities ranging from clots that cause heart attacks and stroke to bleeding disorders.
Rheumatologists at the Annual European Congress of Rheumatology in Vienna, Austria heard today (Thursday 9 June) that rituximab is the first drug in a quarter of a century that is making a real impact, and an alternative to previous standard treatments of high-dose steroids, and chemotherapy.
22nd Century Group, Inc., a company focused on smoking cessation and tobacco harm reduction products, announced today that enrollment of its X-22 Phase II-B clinical trial has been successfully completed; 234 smokers have been randomized in the double-blind, active-controlled, multi-center smoking cessation study.
› Verified 4 days ago
| Entity Name | Henry Ford Health System |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1184708406 PECOS PAC ID: 0547178311 Enrollment ID: O20031111000402 |
News Archive
Research conducted at Leiden has established that guts-on-chips respond in the same way to aspirin as real human organs do. This is a sign that these model organs are good predictors of the effect of medical drugs on the human body. Publication in Nature Communications on 15 August.
Johns Hopkins scientists have launched a pioneering research program to create, for the first time, human platelet cells from stem cells in order to study inherited blood clotting abnormalities ranging from clots that cause heart attacks and stroke to bleeding disorders.
Rheumatologists at the Annual European Congress of Rheumatology in Vienna, Austria heard today (Thursday 9 June) that rituximab is the first drug in a quarter of a century that is making a real impact, and an alternative to previous standard treatments of high-dose steroids, and chemotherapy.
22nd Century Group, Inc., a company focused on smoking cessation and tobacco harm reduction products, announced today that enrollment of its X-22 Phase II-B clinical trial has been successfully completed; 234 smokers have been randomized in the double-blind, active-controlled, multi-center smoking cessation study.
› Verified 4 days ago
| Entity Name | Henry Ford Wyandotte Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1700145851 PECOS PAC ID: 2264334499 Enrollment ID: O20120920000394 |
News Archive
Research conducted at Leiden has established that guts-on-chips respond in the same way to aspirin as real human organs do. This is a sign that these model organs are good predictors of the effect of medical drugs on the human body. Publication in Nature Communications on 15 August.
Johns Hopkins scientists have launched a pioneering research program to create, for the first time, human platelet cells from stem cells in order to study inherited blood clotting abnormalities ranging from clots that cause heart attacks and stroke to bleeding disorders.
Rheumatologists at the Annual European Congress of Rheumatology in Vienna, Austria heard today (Thursday 9 June) that rituximab is the first drug in a quarter of a century that is making a real impact, and an alternative to previous standard treatments of high-dose steroids, and chemotherapy.
22nd Century Group, Inc., a company focused on smoking cessation and tobacco harm reduction products, announced today that enrollment of its X-22 Phase II-B clinical trial has been successfully completed; 234 smokers have been randomized in the double-blind, active-controlled, multi-center smoking cessation study.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Lisa R Rogers, DO 1 Ford Pl Ste 2e, Detroit, MI 48202-3450 Ph: (313) 874-4806 | Lisa R Rogers, DO 2333 Biddle Ave, Wyandotte, MI 48192-4668 Ph: (313) 916-2723 |
News Archive
Research conducted at Leiden has established that guts-on-chips respond in the same way to aspirin as real human organs do. This is a sign that these model organs are good predictors of the effect of medical drugs on the human body. Publication in Nature Communications on 15 August.
Johns Hopkins scientists have launched a pioneering research program to create, for the first time, human platelet cells from stem cells in order to study inherited blood clotting abnormalities ranging from clots that cause heart attacks and stroke to bleeding disorders.
Rheumatologists at the Annual European Congress of Rheumatology in Vienna, Austria heard today (Thursday 9 June) that rituximab is the first drug in a quarter of a century that is making a real impact, and an alternative to previous standard treatments of high-dose steroids, and chemotherapy.
22nd Century Group, Inc., a company focused on smoking cessation and tobacco harm reduction products, announced today that enrollment of its X-22 Phase II-B clinical trial has been successfully completed; 234 smokers have been randomized in the double-blind, active-controlled, multi-center smoking cessation study.
› Verified 4 days ago
Mr. Pawan K Garg, MD Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 2814 Electric, Wyandotte, MI 48192 Phone: 734-284-6050 Fax: 734-284-6552 | |
Dr. Valrie M Honablue, MD Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 2333 Biddle Ave, Wyandotte, MI 48192 Phone: 734-246-6000 | |
Balbir Gandhi, MD Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 2025 Ford Ave, Wyandotte, MI 48192 Phone: 734-281-3080 | |
Dr. Jedd Jack Audry, MD Psychiatry & Neurology Medicare: Medicare Enrolled Practice Location: 2333 Biddle Ave, Wyandotte, MI 48192 Phone: 734-246-7901 | |
Dr. Surjit Singh Mahal, M.D. Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 1404 Biddle Ave, Wyandotte, MI 48192 Phone: 734-324-8000 Fax: 734-324-0993 | |
Mr. Harrison Reed Long, PA Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 375 Eureka Rd Ste B, Wyandotte, MI 48192 Phone: 734-258-8386 Fax: 734-258-8389 |